Dual Pharmacological Targeting of the MAP Kinase and PI3K/mTOR Pathway in Preclinical Models of Colorectal Cancer
Open accessThe DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The activation of the MAPK and PI3K/AKT/mTOR pathways is implicated in the majority of cancers. Activating mutations in both of these pathways has been described in colorectal cancer (CRC), thus indicating their potential as therapeutic targets. This study evaluated the combination of a PI3K/mTOR inhibitor (PF-04691502/PF-502) in combination with a MEK inhibitor (PD-0325901/PD-901) in CRC cell lines and patient-derived CRC tumor xenograft models (PDTX). MATERIALS AND METHODS: The anti-proliferative effects of PF-502 and PD-901 were assessed as single agents and in combination against a panel of CRC cell lines with various molecular backgrounds. Synergy was evaluated using the Bliss Additivity method. In selected cell lines, we investigated the combination effects on downstream effectors by immunoblotting. The combination was then evaluated in several fully genetically annotated CRC PDTX models. RESULTS: The in vitro experiments demonstrated a wide range of IC50 values for both agents against a cell line panel. The combination of PF-502 and PD-901 demonstrated synergistic anti-proliferative activity with Bliss values in the additive range. As expected, p-AKT and p-ERK were downregulated by PF-502 and PD-901, respectively. In PDTX models, following a 30-day exposure to PF-502, PD-901 or the combination, the combination demonstrated enhanced reduction in tumor growth as compared to either single agent regardless of KRAS or PI3K mutational status. CONCLUSIONS: The combination of a PI3K/mTOR and a MEK inhibitor demonstrated enhanced anti-proliferative effects against CRC cell lines and PDTX models.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Indeed, results from several preclinical and clinical studies indicate that dual pharmacological targeting of MAPK and PI3K pathways may be an effective strategy to inhibit the growth of CRC cells, regardless of KRAS or PI3K mutational status [127,128,129,130,131].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [131]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery
Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., & Greenberg, M. E. (1997) · Cell · doi:10.1016/s0092-8674(00)80405-5 · Cited by 5,689
The phosphoinositide 3-kinase pathway
Cantley, L. C. (2002) · Science · doi:10.1126/science.296.5573.1655 · Cited by 5,621
High Frequency of Mutations of the PIK3CA Gene in Human Cancers
Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,437
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
Roberts, P. J., & Der, C. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210422 · Cited by 2,788 · cited 1×
“agents have been developed that target EGFR, RAS, RAF, or MEK, many of which are in clinical trials and some of which are already approved [14].”
BackgroundmTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561 · cited 1×
“Additionally, it is thought that the RAS-RAF-MEK signaling axis may act as a compensatory mechanism with inhibition of the PI3K-AKT-mTOR pathway, and vice versa [18,19].”
BackgroundDe Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144 · cited 15×
“And, the CUCRC042 (KRAS G13D) model was relatively unresponsive to all treatments (Figure 7D).”
BackgroundInfluentialTOR, a Central Controller of Cell Growth
Schmelzle, T., & Hall, M. N. (2000) · Cell · doi:10.1016/s0092-8674(00)00117-3 · Cited by 1,924 · cited 1×
“Cell growth is one of the primary functions governed by mTOR; activation of mTOR via the PI3K/AKT pathway is critical for the cell in balance nutrient uptake and growth, and aberrant hyperactivation of this pathway contributes to tumorigenesis [6,7].”
BackgroundPI3K pathway alterations in cancer: variations on a theme
Yuan, T. L., & Cantley, L. C. (2008) · Oncogene · doi:10.1038/onc.2008.245 · Cited by 1,845 · cited 1×
“PI3K phosphorylates the 3hydroxyl group of phosphatidylinositol, participating in a variety of signaling pathways important for cancer such as proliferation, differentiation, chemotaxis, survival, trafficking, and glucose homeostasis [2,3].”
BackgroundTargeting the PI3K-Akt pathway in human cancer
Luo, J., Manning, B. D., & Cantley, L. C. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00248-4 · Cited by 1,290 · cited 1×
“Because of its diverse cellular function, the PI3K axis is highly implicated in human cancers; up to 30% of all human cancers have a mutation in a PI3K pathway component [4].”
BackgroundPatient-derived tumour xenografts as models for oncology drug development
Tentler, J. J., Tan, A. C., Weekes, C. D., Jimeno, A., Leong, S., Pitts, T. M., Arcaroli, J. J., Messersmith, W. A., & Eckhardt, S. G. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.61 · Cited by 1,277
Self-citationPhosphorylation and Functional Inactivation of TSC2 by Erk
Ma, L., Chen, Z., Erdjument-Bromage, H., Tempst, P., & Pandolfi, P. P. (2005) · Cell · doi:10.1016/j.cell.2005.02.031 · Cited by 1,268
Katso, R., Okkenhaug, K., Ahmadi, K., White, S., Timms, J., & Waterfield, M. D. (2001) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.17.1.615 · Cited by 1,204
Sun, S.-Y., Rosenberg, L. M., Wang, X., Zhou, Z., Yue, P., Fu, H., & Khuri, F. R. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0917 · Cited by 802 · cited 1×
“One benefit of this combination is that through inhibition of the upstream PI3K, feedback upregulation of AKT upon mTOR inhibition is avoided [27].”
BackgroundHoshino, R., Chatani, Y., Yamori, T., Tsuruo, T., Oka, H., Yoshida, O., Shimada, Y., Ari-i, S., Wada, H., Fujimoto, J., et al. (1999) · Oncogene · doi:10.1038/sj.onc.1202367 · Cited by 691 · cited 1×
“Signaling through this pathway results in increased proliferation and resistance to apoptosis, whereas constitutive activation contributes to chemoresistance in several cancers [10,11].”
BackgroundRinehart, J., Adjei, A. A., LoRusso, P. M., Waterhouse, D., Hecht, J. R., Natale, R. B., Hamid, O., Varterasian, M., Asbury, P., Kaldjian, E. P., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.01.185 · Cited by 645 · cited 1×
“However, a more recent Phase II trial with the second generation MEK inhibitor selumetinib demonstrated similar activity to the chemotherapeutic agent capecitabine in CRC patients [37,38].”
BackgroundClass I PI3K in oncogenic cellular transformation
Zhao, L., & Vogt, P. K. (2008) · Oncogene · doi:10.1038/onc.2008.244 · Cited by 594 · cited 1×
“The class I (PI3K) are heterodimeric lipid kinases that comprise a regulatory p85 subunit and a catalytic p110 subunit [1].”
BackgroundChappell, W. H., Steelman, L. S., Long, J. M., Kempf, R. C., Abrams, S. L., Franklin, R. A., Bäsecke, J., Stivala, F., Donia, M., Fagone, P., et al. (2011) · Oncotarget · doi:10.18632/oncotarget.240 · Cited by 510
Morikawa, K., Walker, S. M., Nakajima, M., Pathak, S., Jessup, J. M., & Fidler, I. J. (1988) · PubMed · Cited by 474
Hoeflich, K. P., O'Brien, C., Boyd, Z., Cavet, G., Guerrero, S., Jung, K., Januario, T., Savage, H., Punnoose, E., Truong, T., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0317 · Cited by 463 · cited 1×
“Similarly, in basal-like breast cancer models, an enhanced inhibition of proliferation and an increase in apoptosis was observed in vitro and an increase in tumor growth inhibition was observed in vivo [39].”
BackgroundMao, M., Tian, F., Mariadason, J. M., Tsao, C. C., Lemos, R., Dayyani, F., Gopal, Y. N. V., Jiang, Z.-Q., Wistuba, I. I., Tang, X. M., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1446 · Cited by 290 · cited 1×
“This appears to be due to differential inherent and adaptive feedback/resistance mechanisms that exist among disease subtypes [50,51].”
BackgroundLoRusso, P. M., Krishnamurthi, S. S., Rinehart, J. J., Nabell, L. M., Malburg, L., Chapman, P. B., DePrimo, S. E., Bentivegna, S., Wilner, K. D., Tan, W., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1883 · Cited by 252 · cited 1×
“[23] PD-901 is a highly potent, oral, small-molecule inhibitor of MEK1 and MEK2 that demonstrated some activity in early clinical trials and was associated with toxicities characteristic of this class of agents: rash, diarrhea, fatigue, nausea and visual disturbance, [24].”
BackgroundPIK3CA Mutation in Colorectal Cancer: Relationship with Genetic and Epigenetic Alterations
Nosho, K., Kawasaki, T., Longtine, J. A., Fuchs, C. S., Ohnishi, M., Suemoto, Y., Kirkner, G. J., Zepf, D., Yan, L., & Ogino, S. (2008) · Neoplasia · doi:10.1593/neo.08336 · Cited by 238 · cited 14×
“And, the CUCRC042 (KRAS G13D) model was relatively unresponsive to all treatments (Figure 7D).”
BackgroundInfluentialHaura, E. B., Ricart, A. D., Larson, T. G., Stella, P. J., Bazhenova, L., Miller, V. A., Cohen, R. B., Eisenberg, P. D., Selaru, P., Wilner, K. D., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1920 · Cited by 237
Buck, E., Eyzaguirre, A., Brown, E., Petti, F., McCormack, S., Haley, J. D., Iwata, K. K., Gibson, N. W., & Griffin, G. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0166 · Cited by 234
Ballif, B. A., Roux, P. P., Gerber, S. A., MacKeigan, J. P., Blenis, J., & Gygi, S. P. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409143102 · Cited by 211
Migliardi, G., Sassi, F., Torti, D., Galimi, F., Zanella, E. R., Buscarino, M., Ribero, D., Muratore, A., Massucco, P., Pisacane, A., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2683 · Cited by 191 · cited 2×
“These models are thought to provide significant improvements over typical cell line xenografts, although clinical validation is ongoing [40,44].”
BackgroundPF-04691502, a Potent and Selective Oral Inhibitor of PI3K and mTOR Kinases with Antitumor Activity
Yuan, J., Mehta, P. P., Yin, M.-J., Sun, S., Zou, A., Chen, J., Rafidi, K., Feng, Z., Nickel, J., Engebretsen, J., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0185 · Cited by 163 · cited 2×
“PF-502 is an orally bioavailable, potent ATPcompetitive kinase inhibitor of both class I PI3Ks and mTOR [21,22].”
Backgroundvan den Br�le, F. A., Waltregny, D., Liu, F., & Castronovo, V. (2000) · International Journal of Cancer · doi:10.1002/1097-0215(20000720)89:4<384::aid-ijc11>3.0.co;2-r · Cited by 158 · cited 1×
“Signaling through this pathway results in increased proliferation and resistance to apoptosis, whereas constitutive activation contributes to chemoresistance in several cancers [10,11].”
BackgroundZitzmann, K., von Rüden, J., Brand, S., Göke, B., Lichtl, J., Spöttl, G., & Auernhammer, C. J. (2010) · Cancer Letters · doi:10.1016/j.canlet.2010.02.018 · Cited by 143 · cited 1×
“Additionally, it is thought that the RAS-RAF-MEK signaling axis may act as a compensatory mechanism with inhibition of the PI3K-AKT-mTOR pathway, and vice versa [18,19].”
BackgroundTORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition in BRAF- Mutant Melanoma
Corcoran, R. B., Rothenberg, S. M., Hata, A. N., Faber, A. C., Piris, A., Nazarian, R. M., Brown, R. D., Godfrey, J. T., Winokur, D., Walsh, J., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005753 · Cited by 140 · cited 1×
“For example, in MAPKi sensitive melanoma, treatment with a RAFi or a MEKi, results in decreased pS6, whereas in the insensitive models no decrease in phosphorylation is observed [43].”
BackgroundBRAF inhibitors in cancer therapy
Johansson, C. H., & Brage, S. E. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.11.011 · Cited by 122 · cited 1×
“This appears to be due to differential inherent and adaptive feedback/resistance mechanisms that exist among disease subtypes [50,51].”
BackgroundBennouna, J., Lang, I., Valladares-Ayerbes, M., Boer, K., Adenis, A., Escudero, P., Kim, T.-Y., Pover, G. M., Morris, C. D., & Douillard, J.-Y. (2011) · Investigational New Drugs · doi:10.1007/s10637-010-9392-8 · Cited by 116 · cited 1×
“However, a more recent Phase II trial with the second generation MEK inhibitor selumetinib demonstrated similar activity to the chemotherapeutic agent capecitabine in CRC patients [37,38].”
BackgroundCurrent development of the second generation of mTOR inhibitors as anticancer agents
Zhou, H.-Y., & Huang, S.-L. (2013) · Chinese Journal of Cancer · doi:10.5732/cjc.011.10281 · Cited by 112
Sheppard, K. E., Cullinane, C. M., Hannan, K. M., Wall, M., Chan, J., Barber, F., Foo, J. H., Cameron, D. P., Neilsen, A., Ng, P. Y., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.08.007 · Cited by 88 · cited 1×
“In ovarian cancer co-targeting of the PI3K/mTOR and RAS/MEK pathway demonstrated a synergistic inhibition of proliferation and induction of cell death [42].”
BackgroundDienstmann, R., Serpico, D., Rodon, J., Saura, C., Macarulla, T., Elez, E., Alsina, M., Capdevila, J., Perez-Garcia, J., Sánchez-Ollé, G., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0290 · Cited by 83 · cited 1×
“The choices included second-generation anti-EGFR mAbs (if KRAS wild-type), PI3K pathway inhibitors (if PIK3CA mutation or low PTEN expression), mTORC1 inhibitor plus anti-IGF1R mAb (if low PTEN expression), PI3K pathway inhibitors plus MEK inhibitors (if KRAS or BRAF mutation), BRAF inhibitor (if BRAF mutation) and an…”
BackgroundBritten, C. D., Adjei, A. A., Millham, R., Houk, B. E., Borzillo, G. V., Pierce, K. J., Wainberg, Z. A., & LoRusso, P. M. (2014) · Investigational New Drugs · doi:10.1007/s10637-013-0062-5 · Cited by 82 · cited 1×
“[23] PD-901 is a highly potent, oral, small-molecule inhibitor of MEK1 and MEK2 that demonstrated some activity in early clinical trials and was associated with toxicities characteristic of this class of agents: rash, diarrhea, fatigue, nausea and visual disturbance, [24].”
BackgroundHenderson, Y. C., Chen, Y., Frederick, M. J., Lai, S. Y., & Clayman, G. L. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0062 · Cited by 80 · cited 9×
“However, only in the CUCRC040 model was the level of pERK in the combination group actually lower than both single agent arms.”
BackgroundInfluentialBoasberg, P. D., Redfern, C. H., Daniels, G. A., Bodkin, D., Garrett, C. R., & Ricart, A. D. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1620-1 · Cited by 76
Pitts, T. M., Tan, A. C., Kulikowski, G. N., Tentler, J. J., Brown, A. M., Flanigan, S. A., Leong, S., Coldren, C. D., Hirsch, F. R., Varella-Garcia, M., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3191 · Cited by 69 · cited 2×
“The patient-derived xenografts were generated as previously described [28].”
MethodSelf-citationCotargeting the PI3K and RAS Pathways for the Treatment of Neuroendocrine Tumors
Valentino, J. D., Li, J., Zaytseva, Y. Y., Mustain, W. C., Elliott, V. A., Kim, J. T., Harris, J. W., Campbell, K., Weiss, H. L., Wang, C., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1897 · Cited by 63 · cited 9×
“However, only in the CUCRC040 model was the level of pERK in the combination group actually lower than both single agent arms.”
BackgroundInfluentialCurrent and future directions in mammalian target of rapamycin inhibitors development
Fasolo, A., & Sessa, C. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.541154 · Cited by 58 · cited 1×
“and second generation mTOR inhibitors have been synthesized and are in various stages of clinical and preclinical development [8,9].”
BackgroundAn Update on the Biology of RAS/RAF Mutations in Colorectal Cancer
Nandan, M. O., & Yang, V. W. (2011) · Current Colorectal Cancer Reports · doi:10.1007/s11888-011-0086-1 · Cited by 57 · cited 1×
“Mutations in KRAS, NRAS, or BRAF (all upstream of the MEK complexes) are very common in CRC, and have been found in 50–60% of tumor samples [12,13].”
BackgroundCurrent development of the second generation of mTOR inhibitors as anticancer agents
Hongyu, Zhou, Shi-Le, & Huang (2012) · 癌症:英文版 · Cited by 54
LoRusso, P., Shapiro, G., Pandya, S. S., Kwak, E. L., Jones, C., Belvin, M., Musib, L. C., de Crespigny, A., McKenzie, M., Gates, M. R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.2566 · Cited by 48
Roper, J., Sinnamon, M. J., Coffee, E. M., Belmont, P. J., Keung, L., Richard, L. G., Wang, W. V., Faber, A. C., Yun, J., Yilmaz, Ö. H., et al. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.02.018 · Cited by 44 · cited 1×
“demonstrated that combination PI3K and MEK inhibition promotes apoptosis and tumor regression in mouse models of colorectal cancers [41].”
BackgroundPitts, T. M., Kulikowski, G. N., Tan, A.-C., Murray, B. W., Arcaroli, J. J., Tentler, J. J., Spreafico, A., Selby, H. M., Kachaeva, M. I., McPhillips, K. L., et al. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00035 · Cited by 38 · cited 1×
“Sulforhodamine B assay (SRB) was performed as described previously [30].”
MethodSelf-citationHeist, R. S., Gandhi, L., Shapiro, G. I., Rizvi, N. A., Burris, H. A., Bendell, J. C., Baselga, J. M., Yerganian, S. B., Hsu, K., Ogden, J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.2530 · Cited by 28
Cheng, H., Hoffman, J. E., Le, P. T., Pairish, M., Kania, R. S., Farrell, W. P., Bagrodia, S., Yuan, J., Sun, S., Zhang, E., et al. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.02.020 · Cited by 26 · cited 1×
“PF-502 is an orally bioavailable, potent ATPcompetitive kinase inhibitor of both class I PI3Ks and mTOR [21,22].”
BackgroundYu, M., & Grady, W. M. (2012) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x12448456 · Cited by 26 · cited 1×
“Cell growth is one of the primary functions governed by mTOR; activation of mTOR via the PI3K/AKT pathway is critical for the cell in balance nutrient uptake and growth, and aberrant hyperactivation of this pathway contributes to tumorigenesis [6,7].”
BackgroundBritten, C. D., Wainberg, Z. A., Tabernero, J. M., Alsina, M., Leong, S., Sessa, C., Millham, R., Gallo, J. D., Siu, L. L., & Braña, I. (2012) · European Journal of Cancer · doi:10.1016/s0959-8049(12)72156-1 · Cited by 10
Self-citationThe modern conception of an operating theatre suite.
Towers, M. (1967) · PubMed · Cited by 2
Corcoran, R. B., Rothenberg, S. M., Hata, A. N., Faber, A. C., Winokur, D., Piris, A., Nazarian, R. M., Brown, R. D., Godfrey, J. T., Mino-Kenudson, M. A., et al. (2013) · Cancer Research · doi:10.1158/1538-7445.am2013-4568 · Cited by 2
Cited by
Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers
Temraz, S., Mukherji, D., & Shamseddine, A. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160922976 · Cited by 117
“Similarly, Pitt et al. demonstrated synergistic anti-proliferative activity with the combination of PI3K/mTOR inhibitor PF-502 and the MEK1/2 inhibitor PD-901 [45].”
BackgroundWainberg, Z. A., Alsina, M., Soares, H. P., Braña, I., Britten, C. D., Del Conte, G., Ezeh, P., Houk, B., Kern, K. A., Leong, S., et al. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0530-5 · Cited by 98
Self-citationMossenta, M., Busato, D., Bo, M. D., & Toffoli, G. (2020) · Cancers · doi:10.3390/cancers12061668 · Cited by 98
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
“Indeed, results from several preclinical and clinical studies indicate that dual pharmacological targeting of MAPK and PI3K pathways may be an effective strategy to inhibit the growth of CRC cells, regardless of KRAS or PI3K mutational status [127–131].”
Recent contributions of quinolines to antimalarial and anticancer drug discovery research
de Walle, T. V., Cools, L., Mangelinckx, S., & D’hooghe, M. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113865 · Cited by 86
Metadata
- Authors
- Pitts, T. M., Newton, T. P., Bradshaw-Pierce, E. L., Addison, R., Arcaroli, J. J., Klauck, P. J., Bagby, S. M., Hyatt, S. L., Purkey, A., Tentler, J. J., Tan, A. C., Messersmith, W. A., Eckhardt, S. G., & Leong, S.
- Affiliations
- University of Colorado Cancer Center (US)
- University of Colorado Anschutz (US)
- Corresponding author
- Pitts, Todd M.
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-11-17
- Volume
- 9
- Issue
- 11
- Pages
- e113037
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4234626
- OpenAlex
- W2020016981
- Cited by
- 54
- References
- 53
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 5 · 2023: 3 · 2022: 5 · 2021: 6 · 2020: 7 · 2019: 3 · 2018: 7 · 2017: 4 · 2016: 4 · 2015: 4
- FWCI
- 1.64
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Pfizer
- Cancer Center, University of Colorado (P30 CA046934, CA046934)
- National Cancer Institute (P30CA046934)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Keywords
- colorectal cancer, PI3K/mTOR inhibition, MEK inhibition, combination therapy, MAPK signaling, PI3K/AKT/mTOR pathway, patient-derived xenografts, drug synergy, KRAS mutation, PI3K mutations, Akt phosphorylation, ERK1/2 phosphorylation, antiproliferative activity
- MeSH terms
- Phosphoinositide-3 Kinase Inhibitors, Animals, Antineoplastic Combined Chemotherapy Protocols, Benzamides, Diphenylamine, Drug Synergism, Female, Humans, Mice, Nude, Immunoblotting, Colorectal Neoplasms, Signal Transduction, Phosphatidylinositol 3-Kinases, Mitogen-Activated Protein Kinases, Xenograft Model Antitumor Assays, Cell Line, Tumor, Protein Kinase Inhibitors, Cell Proliferation, Mice, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.